$1.47
+0.08 (+5.76%)
Open$1.40
Previous Close$1.39
Day High$1.47
Day Low$1.39
52W High$4.42
52W Low$1.05
Volume—
Avg Volume689.9K
Market Cap55.02M
P/E Ratio—
EPS$-2.02
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+2,798.6% upside
Current
$1.47
$1.47
Target
$42.61
$42.61
$22.54
$42.61 avg
$49.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 27.49M | 26.17M | 29.17M |
| Net Income | -6,413,122 | -6,638,758 | -7,979,028 |
| Profit Margin | -23.3% | -25.4% | -27.4% |
| EBITDA | -10,041,478 | -10,799,684 | -11,152,703 |
| Free Cash Flow | -6,132,912 | -6,792,749 | -5,207,622 |
| Rev Growth | +12.4% | +6.3% | +17.3% |
| Debt/Equity | 0.29 | 0.25 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |